Abstracts, surgical videos, and case presentations are now being accepted for presentation consideration at the 2024 STS Coronary Conference, taking place June 7-8, 2024, in Miami, Florida. Submissions will be accepted until Friday, March 1, 2024.
During the webinar, healthcare professionals, including surgeons, trainees, and interventional cardiologists, will gain a comprehensive understanding of the current state of valve surgery and the role of transcatheter therapies. The expert faculty will explore educational gaps in this space, with the goal of fostering knowledge-sharing and collaboration, ultimately improving patient outcomes.
Rohun Bhagat, MD
Chi Chi Do-Nguyen, DO
University of Michigan
Ann Arbor, MI
Hear about the invaluable benefits of becoming an active and involved member of STS, your career journey partner. Involvement opportunities to be discussed include joining a task force or workforce, becoming an advocate on healthcare policy, and developing new tools and resources to improve patient care.
This webinar aims to help early career surgeons and trainees learn objectives and strategies for negotiating a contract. The session covers a wide range of negotiation elements from preparation to health insurance considerations to signing bonuses.
This presentation on day one of STS 2024 will report on a comprehensive approach that focuses on maximizing survival and optimizing the utilization of donor hearts in patients with hypoplastic left heart syndrome (HLHS) and HLHS-related malformations with functionally univentricular ductal-dependent systemic circulation.
“A Comprehensive Approach to the Management of Patients with HLHS and HLHS-Related Malformation” will begin at 9:45 a.m. CT in room Stars at Night 1. The presentation is part of the STS “Cardiac Center in Evolution: Management of Single Ventricle” session.
Dr. Mark Bleiweis, from the University of Florida, will report on findings describing outcomes that resulted from using this approach in 100 consecutive neonates. During the talk, Dr. Bleiweis will detail how these neonates with HLHS and HLHS-related malformations, during an eight-year period, were stratified into three different pathways based on their risk factors, and mortality rates that resulted for these neonates.
“This study is based on the principle that some patients with HLHS or HLHS-related malformations are at very high-risk for Norwood (Stage 1) palliation or hybrid palliation secondary to important cardiac risk factors,” said Dr. Bleiweis.